Domov › Rakovina pľúc › Delaware
Klinické štúdie Rakovina pľúc v štáte Delaware
11 štúdií pre Rakovina pľúc hľadá účastníkov v zariadeniach v štáte Delaware.
Mestá v štáte Delaware
Oficiálny text štúdie (anglicky)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- a 1 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT04267848The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Medical Oncology Hematology Consultants, Newark
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT04585750Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- a 1 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06498635A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark
Prebieha náborFáza 3
Vek 18 až 100 · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT05920356A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- ChristianaCare Health System, Newark
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07154290Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Beebe Medical Center, Lewes
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- a 4 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 8. 2026 · NCT05624996Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Bayhealth Hospital Kent Campus, Dover
- Bayhealth Hospital Sussex Campus, Milford
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 6. 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Bayhealth Hospital Kent Campus, Dover
- Bayhealth Hospital Sussex Campus, Milford
Prebieha náborFáza 2
18 Minutes · Všetky pohlavia · Aktualizované 5. 5. 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- a 1 ďalších
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 5. 2026 · NCT06616584LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- a 3 ďalších
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 1. 2026 · NCT06073431SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Newark
Prebieha náborObservačná štúdia
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 28. 10. 2025 · NCT03452774Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.